City

Clinical trials near Chongqing, China

Active studies with a listed research site in Chongqing, China.

23active studies

6recruiting now

11countries represented

187largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowNot applicable

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Obesity, Weight ControlCondition

Mazdutide, Intensive Lifestyle InterventionTreatment

China13 locations

Shanghai Zhongshan HospitalSponsor

Updated 2026-04-08 · NCT07517042See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 3

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

ObesityCondition

TQF3510 (Semaglutide Injection), Wegovy®Treatment

China66 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2024-12-18 · NCT06738979See eligibility →

Active, not recruitingNot applicable

Time-Restricted Eating for Weight-Loss Maintenance

Overweight or Obese AdultsCondition

Scheduled Weight Maintenance Nutrition Education, Time-Restricted Eating (10-Hour Window)Treatment

China10 locations

Harbin Medical UniversitySponsor

Updated 2026-08-25 · NCT07163455See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 3

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

Overweight , ObesityCondition

Zovaglutide dose 1, Zovaglutide dose 2Treatment

China45 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-08-03 · NCT07230119See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingNot applicable

Organic Pollutant Build-Up in Body Fat and Stomach Tissue Linked to Obesity Levels

Obesity &Amp; OverweightCondition

exposure to organic pollutantTreatment

China1 locations

Dong PengSponsor

Updated 2025-08-17 · NCT07126743See eligibility →

Active, not recruitingNot applicable

The Effects of Environmental Factors on the Macro-genome and Metabolism of Obese Patients.

Obesity and OverweightCondition

obesity, healthTreatment

China1 locations

Dong PengSponsor

Updated 2025-06-02 · NCT06673433See eligibility →

Active, not recruitingNot applicable

Identification of Microplastics in Liver, Stomach, Blood, and Feces of Obese Patients and Their Association Analysis with Macrogenomics and Metabolomics.

Obesity and OverweightCondition

Measuring the microplasticsTreatment

China1 locations

First Affiliated Hospital of Chongqing Medical UniversitySponsor

Updated 2025-02-14 · NCT06826586See eligibility →

Active, not recruitingNot applicable

A Clinical Study of the Effects of Environmental Pollution on Obesity

Obesity and OverweightCondition

ObesityTreatment

China3 locations

Dong PengSponsor

Updated 2024-11-01 · NCT06670703See eligibility →

Active, not recruitingNot applicable

Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients

Colorectal Cancer, SarcopeniaCondition

abdominal fat and muscle areaTreatment

China3 locations

First Affiliated Hospital of Chongqing Medical UniversitySponsor

Updated 2024-09-27 · NCT06614699See eligibility →

Active, not recruitingNot applicable

Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients

Gastric Cancers, Colorectal CancerCondition

Skeletal muscle, subcutaneous fat and visceral fat areaTreatment

China3 locations

First Affiliated Hospital of Chongqing Medical UniversitySponsor

Updated 2024-09-23 · NCT06606912See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Chongqing, China

Current studies

Related cities